» Articles » PMID: 39833570

Co-delivery of IL-1Ra and SOX9 Via AAV Inhibits Inflammation and Promotes Cartilage Repair in Surgically Induced Osteoarthritis Animal Models

Overview
Journal Gene Ther
Date 2025 Jan 20
PMID 39833570
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA), a prevalent joint disorder, can lead to disability, with no effective treatment available. Interleukin-1 (IL-1) plays a crucial role in the progression of OA, and its receptor antagonist (IL-1Ra), a natural IL-1 inhibitor, represents a promising therapeutic target by obstructing the IL-1 signaling pathway. This study delivered IL-1Ra via adeno-associated virus (AAV), a gene therapy vector enabling long-term protein expression, to treat knee osteoarthritis (KOA) in animal models. scAAV-oIL-1Ra-I1/2 injected directly into the joint in both MMT/ACLT-induced KOA model rat improved abnormal gait (increasing footprint area and pressure), subchondral bone lesions, and significantly reduced cartilage wear and pathological scores. In the MMT-induced KOA rabbit model, weight-bearing asymmetry (indicating pain) improved after 8 weeks of scAAV-oIL-1Ra-I1/2 administration, and X-ray showed decreased K-L scores (severity grade), reduced cartilage loss, and lower pathology scores compared to untreated animals. Additionally, sex-determining region Y-type high mobility group box 9 (SOX9) was co-delivered with IL-1Ra via AAV in ACLT + MMT-induced KOA rats. The combined treatment significantly alleviated subchondral bone lesions, cartilage destruction, synovial inflammation, and pathological scores, demonstrating superior efficacy compared to either treatment administered alone. Co-delivering IL-1Ra and SOX9 inhibited IL-1 mediated inflammatory signaling, maintained cartilage homeostasis, and promoted its repair in KOA models, suggesting potential for clinical use.

References
1.
Chen D . Osteoarthritis: A complicated joint disease requiring extensive studies with multiple approaches. J Orthop Translat. 2022; 32:130. PMC: 9072797. DOI: 10.1016/j.jot.2022.02.009. View

2.
Li Y, Xie W, Xiao W, Dou D . Progress in osteoarthritis research by the National Natural Science Foundation of China. Bone Res. 2022; 10(1):41. PMC: 9130253. DOI: 10.1038/s41413-022-00207-y. View

3.
Austine J, Nair S, Mirza K . Perspective of Orthopedists on Pain Management in Osteoarthritis: A Qualitative Study. Indian J Palliat Care. 2016; 22(4):410-415. PMC: 5072232. DOI: 10.4103/0973-1075.191764. View

4.
Chen D, Shen J, Zhao W, Wang T, Han L, Hamilton J . Osteoarthritis: toward a comprehensive understanding of pathological mechanism. Bone Res. 2017; 5:16044. PMC: 5240031. DOI: 10.1038/boneres.2016.44. View

5.
Vincent T, Alliston T, Kapoor M, Loeser R, Troeberg L, Little C . Osteoarthritis Pathophysiology: Therapeutic Target Discovery may Require a Multifaceted Approach. Clin Geriatr Med. 2022; 38(2):193-219. PMC: 9107912. DOI: 10.1016/j.cger.2021.11.015. View